PPARA and melanoma: Previous studies revealed that PPARƴ agonists, including troglitazone, rosiglitazone, and 15d-PGJ2, inhibited the proliferation of human melanoma cell lines in a dose-dependent manner and induced cell cycle arrest, whereas no effect was observed in melanoma cells exposed to PPARα agonist WY-14643 [26].